Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors

Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors

Tumors arising in the context of Lynch Syndrome or constitutional mismatch repair deficiency are hypermutated and have a good response towards immune-checkpoint inhibitors (ICIs), including α-PD-L1 antibodies. However, in most cases, resistance mechanisms evolve. To improve outcomes and prevent resi...

Full description

Bibliographic Details
Main Authors: Inken Salewski, Julia Henne, Leonie Engster, Bjoern Schneider, Heiko Lemcke, Anna Skorska, Peggy Berlin, Larissa Henze, Christian Junghanss, Claudia Maletzki
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:International Journal of Molecular Sciences
Subjects:
immune checkpoint inhibitor
MMR deficiency
in vivo imaging
tumor microenvironment
genetic model
coding microsatellite mutations
Online Access:https://www.mdpi.com/1422-0067/22/11/5990

Similar Items

Similar Items